RxDoctor Payments Data

David Corral, MD

Internal Medicine · Benbrook, TXNPI 1003846882

Payments from drug & device makers

$1,397in general payments, 2019–2025

Across 32 payments — averaging $43.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$405
  • Abbott$345
  • Nevro Corp.$182
  • AbbVie$172
  • E.r. Squibb & Sons, L.L.C.$121
  • Haemonetics Corporation$80
  • plus $91 from 5 others

What the payments were for

  • Food & beverage$1,397100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,397 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$210,882
Medicare patients
145
Services billed
2,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriparatide13$43,217
Tresiba Flextouch U-200Insulin Degludec15$22,913
EliquisApixaban16$20,494
VascepaIcosapent Ethyl13$11,715
Humalog Kwikpen U-100Insulin Lispro11$8,118
Metoprolol Succinate263$4,166
Icosapent Ethyl12$3,869
Gabapentin118$3,779
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$3,758
SymbicortBudesonide/Formoterol Fumarate11$2,626
Rosuvastatin Calcium185$2,475
Ezetimibe182$2,292
Atorvastatin Calcium250$1,764
Ultra-Fine Short Pen NeedlePen Needle, Diabetic11$1,633
Amlodipine Besylate190$1,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskNovolog$15$91511 claims
AbbVieSynthroid$172$80621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Benbrook

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →